which glp 1 agonists are approved for weight loss GLP-1 medications Glucagon-like peptide 1 receptor agonists

obesity - by administration of the proglucagon fragment GLP-1(1-45), or its fragment, analogue or amide

Since GLP-1 is prone to degradation by dipeptidyl peptidase 4, GLP-1 receptor agonists (GLP-1RAs) have been developed to surmount this degradation challenge

A pooled analysis of CVOTs showing that therapy with GLP-1 RA does not increase the risk of acute pancreatitis or pancreatic cancer

ACKNOWLEDGEMENTS We thank Alexander Jones, AXON Communications, for medical writing and editorial assistance (funded by Novo Nordisk A/S)

The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database

Unique Features: Semaglutide is the first GLP-1RA shown to reduce cardiovascular events in non-diabetic individuals, making it a notable choice for obesity management